Xiao Hui Gu
Nessuna posizione attualmente
Storia della carriera di Xiao Hui Gu
Precedenti posizioni note di Xiao Hui Gu
Società | Posizione | Inizio | Fine |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2008 | 01/01/2008 |
EXELIXIS, INC. | Corporate Officer/Principal | - | - |
PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | 01/05/2011 | - |
Formazione di Xiao Hui Gu
Hunan Normal University | Undergraduate Degree |
Shanghai Institute of Organic Chemistry | Doctorate Degree |
Statistiche
Distribuzione geografica
Cina | 4 |
Stati Uniti | 3 |
Posizioni
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Settori
Commercial Services | 3 |
Consumer Services | 3 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
PHARMARON BEIJING CO., LTD. | Commercial Services |
EXELIXIS, INC. | Health Technology |
Aziende private | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Borsa valori
- Insiders
- Xiao Hui Gu
- Esperienza